An online-based mindfulness treatment program significantly reduced opioid craving among participants with opioid use disorder results from a randomized clinical trial published in JAMA Network Open ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Ontario’s associate minister of mental health and addictions says the best way to curb the number of people entering the ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

It may be, she added, that weekly therapy sessions are simply not scalable to a broad population, and the field should explore light-touch alternatives, like single-session interventions and ...

Get Instant Summarized Text (Gist) The delta opioid receptor (DOP) is identified as a promising target for developing rapid-acting antidepressants with minimal side effects. Selective DOP agonists ...

Working as a long-acting full opioid agonist, methadone reduces opioid craving and withdrawal. Expanding access could transform the treatment landscape. “If you came in for a heart attack ...